Evidence map›Paper›PMID 30653926›Full record

Trial reportAnnals of the American Thoracic Society2019

Safety and Tolerability of Comprehensive Research Bronchoscopy in Chronic Obstructive Pulmonary Disease. Results from the SPIROMICS Bronchoscopy Substudy.

J Michael Wells, Douglas A Arenberg, Igor Barjaktarevic, Surya P Bhatt, Russell P Bowler, Stephanie A Christenson, David J Couper, Mark T Dransfield, MeiLan K Han, Eric A Hoffman and 13 more

Registry-linked trialAbstract readClinical TrialMulticenter Study
In one paragraph

Trial report in Annals of the American Thoracic Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01969344 (Subpopulations and Intermediate Outcome Measures in COPD Study), which is not on this map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
2.4field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01969344 active not recruitingnot on this map

Subpopulations and Intermediate Outcome Measures in COPD Study

TypeobservationalSponsorUniversity of North Carolina, Chapel HillRan2010 to 2031Enrolled2,981ConditionsCOPD, Chronic Obstructive Pulmonary Disease, Chronic Bronchitis, Emphysema
3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 31 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Article
  8. Design of the SPIROMICS Study of Early COPD Progression: SOURCE Study.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024
    Article
  9. Article
  10. Bronchial Rheoplasty for Chronic Bronchitis: Results from a Canadian Feasibility Study with RheOxInternational journal of chronic obstructive pulmonary disease · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 14 institutions in 2 countries.

J Michael Wells1 Division of Pulmonary, Allergy, and Critical Care Medicine, and.
Douglas A Arenberg4 Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.
Igor Barjaktarevic5 Division of Pulmonary and Critical Care Medicine, University of California, Los Angeles, Los Angeles, California.
Surya P Bhatt1 Division of Pulmonary, Allergy, and Critical Care Medicine, and.
Russell P Bowler6 Division of Pulmonary and Critical Care Medicine, National Jewish Health, Denver, Colorado.
Stephanie A Christenson8 Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California.
David J Couper9 Marsico Lung Institute, Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina.
Mark T Dransfield1 Division of Pulmonary, Allergy, and Critical Care Medicine, and.
MeiLan K Han4 Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.
Eric A Hoffman10 Department of Radiology, University of Iowa, Iowa City, Iowa.
Robert J Kaner11 Departments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, New York.
Victor Kim12 Department of Thoracic Medicine and Surgery, Lewis Katz School of Medicine, Temple University, Philadelphia, Pennsylvania.
Eric Kleerup13 Wake Forest University, Winston-Salem, North Carolina.
Fernando J Martinez11 Departments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, New York.
Wendy C Moore13 Wake Forest University, Winston-Salem, North Carolina.
Sarah L O'Beirne11 Departments of Medicine and Genetic Medicine, Weill Cornell Medicine, New York, New York.ORCID 0000-0003-2876-0258
Robert Paine14 Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, Utah.
Nirupama Putcha16 Division of Pulmonary and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland.
Sanjeev M Raman14 Division of Respiratory, Critical Care, and Occupational Pulmonary Medicine, University of Utah, Salt Lake City, Utah.
R Graham Barr17 Division of Pulmonary, Allergy, and Critical Care Medicine, Columbia University, New York, New York.
Stephen I Rennard18 IMED Biotech Unit, AstraZeneca, Cambridge, United Kingdom.
Prescott G Woodruff8 Division of Pulmonary and Critical Care Medicine, University of California, San Francisco, San Francisco, California.
Jeffrey L Curtis4 Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0001-5191-4847
Cornell University · USUniversity of Alabama at Birmingham · USUniversity of Michigan · USUniversity of California, San Francisco · USUniversity of Utah · USWake Forest University · USAstraZeneca (United Kingdom) · GBColumbia University · USJohns Hopkins University · USNational Jewish Health · USTemple University · USUniversity of California, Los Angeles · USUniversity of Iowa · USUniversity of North Carolina at Chapel Hill · US

Funding

Vector Core-Core 2P30DK054759 · NIDDK · UNIVERSITY OF IOWA · PI Amy Leanne Ryan · 1998 to 2026
$30.5M
SPIROMICS II: Biological underpinnings of COPD heterogeneity and progressionU01HL137880 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WOODRUFF, PRESCOTT G · 2017 to 2021
$27.9M
SPIROMICS GIC SupportU24HL141762 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COUPER, DAVID J, O'NEAL, WANDA K · 2018 to 2022
$7.2M
Ultra-low Dose, High Speed, High Resolution, Multispectral, Multi-Source MDCT ScaS10OD018526 · OD · UNIVERSITY OF IOWA · PI HOFFMAN, ERIC ALFRED · 2015 to 2015
$2.0M
Mentoring Research in Precision Medicine for Lung DiseaseK24HL137013 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI PRESCOTT G WOODRUFF · 2017 to 2026
$1.2M
Identifying the Th2 endotype in COPD: clinical and pathologic implicationsK23HL123778 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHRISTENSON, STEPHANIE A · 2015 to 2019
$847k
The Role of PGP in COPD-associated Pulmonary HypertensionK08HL123940 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WELLS, JAMES MICHAEL · 2014 to 2018
$744k
UAB Mentoring Program in COPD Patient Oriented ResearchK24HL140108 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI DRANSFIELD, MARK T · 2018 to 2022
$439k
Modulation of Steroid Suppression by Alveolar Macrophage EfferocytosisI01CX000911 · VA · VETERANS HEALTH ADMINISTRATION · PI CURTIS, JEFFREY LOUIS · 2016 to 2020
–
CSRD VA I01 CX000911NHLBI NIH HHS HHSN268200900013CNHLBI NIH HHS HHSN268200900014CNHLBI NIH HHS HHSN268200900015CNHLBI NIH HHS HHSN268200900016CNHLBI NIH HHS HHSN268200900017CNHLBI NIH HHS HHSN268200900018CNHLBI NIH HHS HHSN268200900019CNHLBI NIH HHS HHSN268200900020CNHLBI NIH HHS K08 HL123940NHLBI NIH HHS K23 HL123778NHLBI NIH HHS K24 HL137013NHLBI NIH HHS K24 HL140108NHLBI NIH HHS U01 HL137880NHLBI NIH HHS U24 HL141762NIDDK NIH HHS P30 DK054759NIH HHS S10 OD018526WHI NIH HHS HHSN268200900009C
6 · The paper itself

Abstract

rationaleThere is an unmet need to investigate the lower airways in chronic obstructive pulmonary disease (COPD) to define pathogenesis and to identify potential markers to accelerate therapeutic development. Although bronchoscopy is well established to sample airways in various conditions, a comprehensive COPD research protocol has yet to be published.

objectivesTo evaluate the safety and tolerability of a comprehensive research bronchoscopy procedure suitable for multicenter trials and to identify factors associated with adverse events.

methodsWe report the detailed methodology used to conduct the bronchoscopy used in SPIROMICS (the Subpopulations and Intermediate Outcome Measures in COPD Study). The protocol entailed collection of tongue scrapings and oral rinses as well as bronchoscopy with airway inspection, bronchoalveolar lavage (BAL), protected brushings, and endobronchial biopsies. Visual airway characteristics were graded on a scale of 0 (normal appearance) to 3 (severe abnormality) in four domains: erythema, edema, secretions, and friability. Adverse events were defined as events requiring intervention. Logistic regression modeling assessed associations between adverse event occurrence and key variables.

resultsWe enrolled 215 participants. They were 61 ± 9 years old, 71% were white, 53% were male, and post-bronchodilator forced expiratory volume in 1 second was 89 ± 19% predicted. Self-reported asthma was present in 22% of bronchoscopy participants. Oral samples were obtained in greater than or equal to 99% of participants. Airway characteristics were recorded in 99% and were most often characterized as free of edema (61.9%). Less than 50% reported secretions, friability, or erythema. BAL yielded 111 ± 57 ml (50%) of the 223 ± 65 ml of infusate, brushes were completed in 98%, and endobronchial biopsies were performed in 82% of procedures. Adverse events requiring intervention occurred in 14 (6.7%) of 208 bronchoscopies. In logistic regression models, female sex (risk ratio [RR], 1.10; 95% confidence interval [CI], 1.02-1.19), self-reported asthma (RR, 1.17; 95% CI, 1.02-1.34), bronchodilator reversibility (RR, 1.17; 95% CI, 1.04-1.32), COPD (RR, 1.10; 95% CI, 1.02-1.20), forced expiratory volume in 1 second (RR, 0.97; 95% CI, 0.95-0.99), and secretions (RR, 1.85; 1.08-3.16) or friability (RR, 1.64; 95% CI, 1.04-2.57) observed during bronchoscopy were associated with adverse events.

conclusionsA research bronchoscopy procedure that includes oral sampling, BAL, endobronchial biopsy, and brushing can be safely performed. Airway characteristics during bronchoscopy, demographics, asthma or COPD, and lung function may convey increased risk for procedure-related events necessitating intervention.

Indexed as

AgedAsthmaBiopsyBronchiBronchoalveolar LavageBronchoscopyChest PainCohort StudiesComorbidityDyspneaFemaleForced Expiratory VolumeHumansLogistic ModelsMaleMiddle Agedbronchoscopychronic obstructive pulmonary diseasemethodology/protocolsafety

Identifiers

PMID30653926
PMCPMC6441692
OpenAlexW2934656642

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.